Following on from information provided to NICE by the company in July 2018, the appraisal of Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 913
Email enquiries
If you have any queries please email scheduling@nice.org.uk
- External Assessment Group:
- BMJ Evidence Centre, BMJ Group
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Note added to the project documents |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in July 2018, the appraisal of Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 17 December 2018 | Note added to the project documents |
| 09 April 2018 | Suspended. On 22 March 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Dexxience (betrixaban), intended for the prevention of venous thromboembolism in acutely ill medical patients. Consequently the first appraisal committee discussion of this topic has been cancelled and NICE have suspended the appraisal. We will continue to monitor any developments and will update interested parties if the situation changes. |
| 19 March 2018 | Note added to the project documents |
| 03 November 2017 | Invitation to participate |
| 25 January 2017 | Draft scope documents |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual